Absci to Participate in Upcoming Investor Conferences

GlobeNewswire

03-26

VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

H.C. Wainwright 2^nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time

24^th Annual Needham Virtual Healthcare Conference
Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time

Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor Contact
Alex Khan
VP, Finance & Investor Relations
investors@absci.com

Media Contact
press@absci.com

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2522807384"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2522807384\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2522807384?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 20:00","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2522807384","market":"us","top_or_hot":-1,"title":"Absci to Participate in Upcoming Investor Conferences","media":"GlobeNewswire","content":"<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/WEDcoBx1ixtoZz_n0cG9XA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/42d59199135e8e78f2ae46a2458d8373\" title=\"Absci-NameLogo.png\" vspace=\"5\"/>\n<p>VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.</p>\n<ul type=\"disc\">\n<li><strong>H.C. Wainwright 2</strong><sup><strong>nd</strong></sup><strong> Annual Artificial Intelligence Based Drug Discovery &amp; Development Virtual Conference<br/></strong>Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time</li>\n</ul>\n<ul type=\"disc\">\n<li><strong>24</strong><sup><strong>th</strong></sup><strong> Annual Needham Virtual Healthcare Conference<br/></strong>Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time</li>\n</ul>\n<p>Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: <u>investors.absci.com</u>.</p>\n<p><strong>About Absci</strong></p>\n<p><u>Absci</u> is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our <u>Integrated Drug Creation</u>™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit <u>www.absci.com</u> and follow us on LinkedIn (<u>@absci</u>), X (Twitter) (<u>@Abscibio</u>), and <u>YouTube</u>.</p>\n<p><strong>Investor Contact</strong><br/>Alex Khan<br/>VP, Finance &amp; Investor Relations<br/>investors@absci.com<br/><br/><br/></p>\n<p><strong>Media Contact</strong><br/>press@absci.com<br/></p>\n<br/></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci to Participate in Upcoming Investor Conferences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci to Participate in Upcoming Investor Conferences\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">GlobeNewswire</strong><span class=\"h-time small\">2025-03-26 20:00</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><img hspace=\"5\" src=\"https://s1.yimg.com/uu/api/res/1.2/WEDcoBx1ixtoZz_n0cG9XA--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/globenewswire.com/42d59199135e8e78f2ae46a2458d8373\" title=\"Absci-NameLogo.png\" vspace=\"5\"/>\n<p>VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.</p>\n<ul type=\"disc\">\n<li><strong>H.C. Wainwright 2</strong><sup><strong>nd</strong></sup><strong> Annual Artificial Intelligence Based Drug Discovery &amp; Development Virtual Conference<br/></strong>Fireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time</li>\n</ul>\n<ul type=\"disc\">\n<li><strong>24</strong><sup><strong>th</strong></sup><strong> Annual Needham Virtual Healthcare Conference<br/></strong>Fireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time</li>\n</ul>\n<p>Interested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: <u>investors.absci.com</u>.</p>\n<p><strong>About Absci</strong></p>\n<p><u>Absci</u> is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our <u>Integrated Drug Creation</u>™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit <u>www.absci.com</u> and follow us on LinkedIn (<u>@absci</u>), X (Twitter) (<u>@Abscibio</u>), and <u>YouTube</u>.</p>\n<p><strong>Investor Contact</strong><br/>Alex Khan<br/>VP, Finance &amp; Investor Relations<br/>investors@absci.com<br/><br/><br/></p>\n<p><strong>Media Contact</strong><br/>press@absci.com<br/></p>\n<br/></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://finance.yahoo.com/news/absci-participate-upcoming-investor-conferences-120000036.html\">GlobeNewswire</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://finance.yahoo.com/news/absci-participate-upcoming-investor-conferences-120000036.html","article_id":"2522807384","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522807384","pubTimestamp":1742990400,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"VANCOUVER, Wash. and NEW YORK, March 26, 2025  -- Absci Corporation , a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.H.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time. 24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ABSI":"Absci Corporation.","BK4139":"生物科技","BK4121":"生命科学工具和服务"},"translate_title":"Absci将参加即将举行的投资者会议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":0.9},"content_text":"VANCOUVER, Wash. and NEW YORK, March 26, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.\n\nH.C. Wainwright 2nd Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceFireside chat on Wednesday, April 2 at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time\n\n\n24th Annual Needham Virtual Healthcare ConferenceFireside chat on Tuesday, April 8 at 3:45 p.m. Eastern Time / 12:45 p.m. Pacific Time\n\nInterested parties may access live and archived webcasts of the fireside chat sessions on the company’s investor relations website at: investors.absci.com.\nAbout Absci\nAbsci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.\nInvestor ContactAlex KhanVP, Finance & Investor Relationsinvestors@absci.com\nMedia Contactpress@absci.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}